Asthma Clinical Trial
— IDEALOfficial title:
An Open Feasibility Study to Investigate the Impact of A Digitally Delivered Asthma Service for Patients in Primary Care (IDEAL-001: Integrated Digitally EnhAnced Care for Long-term Conditions-001
NCT number | NCT03511482 |
Other study ID # | IDEAL 001 |
Secondary ID | |
Status | Withdrawn |
Phase | N/A |
First received | |
Last updated | |
Start date | March 8, 2019 |
Est. completion date | March 31, 2021 |
Verified date | March 2019 |
Source | my mhealth Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Asthma is a common lung condition that causes long term breathing difficulties. There is
currently no cure for asthma but the use of simple inhaler treatments can keep the symptoms
under control. If asthma symptoms get worse this can lead to an asthma attack which can be
life-threatening. It has been shown that most of the deaths related to asthma are preventable
if asthma is managed using the correct treatment plan however a significant proportion of
patients are not using the right inhalers or not using them properly and do not know how to
manage their asthma if it gets worse.
There is currently an unmet need to develop tools that can help improve asthma care, identify
high risk patients, closely monitor their asthma control in 'real time' and intervene to
optimise treatment to prevent asthma attacks. Both patients and indeed, the current British
Thoracic Society (BTS) asthma guidelines recognise that technology has the potential to be
used to improve asthma care and could lead to reductions in National Health Service (NHS)
services use and improvements in symptoms.
Patients with better controlled asthma are less likely to be admitted to hospital and more
likely to have an improved quality of life. This study aims to evaluate the delivery of an
asthma service using an online doctor providing remote consultations paired with a
self-management asthma app. The patients will use the app to input and track their symptoms,
which will be monitored by a doctor remotely who can provide advice, optimise medications and
intervene in a timely manner to prevent an asthma attack. The service is interactive, so the
patient and doctor can communicate with one another 7 days a week by completing a
consultation or sending messages via the online doctor portal or speaking on the telephone.
The app will relay information about environmental triggers to the patient to help prevent
the patient's asthma getting worse. The service will provide a new and potentially more
convenient way of delivering routine appointments to reduce the numbers that do not attend.
The patients will be able to watch educational videos stored on the app about asthma to
potentially improve understanding of their condition. Digital training in inhaler technique
will be supported with face to face support from pharmacists.
The goals are to increase adherence to and correct use of medication, help patients
self-manage dynamically to reduce their risk of an asthma attack (with solutions personalised
to an individual's triggers) and equip healthcare professionals with the data to identify
those people at higher risk of an attack.
This is a before-and-after open interventional study, which means participants' asthma
control will be compared before and after using the digital asthma management service. It is
not a randomised study and participants will be given the choice of using a digital service.
It is a single-centre study which will take place within one Clinical Commissioning Group
(CCG) in Hampshire (UK), across at least two GP surgeries. It is anticipated that
approximately 80 patients will be recruited.
Patients will be provided with this digital asthma service for a period of 6 months of 2018
and outcomes will be measured using a combination of questionnaires (quality of life, patient
satisfaction, level of activation) and quantitative measures such as Forced Expired Volume
over 1 second (FEV1)(measure of airway obstruction), Fractional Exhaled Nitric Oxide (FENO)
(measure of airway inflammation) and Asthma Control Test Scores (measure of symptom control).
Feedback from NHS professionals hosting the study and online doctors will also be sought. A
Health economic model will be generated comparing the digitally enhanced model versus usual
care. The main outcome of this study is looking at whether this new model of service delivery
can provide an improvement in asthma control test scores.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | March 31, 2021 |
Est. primary completion date | March 31, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility |
Inclusion Criteria: - Adult patients aged 18 years and over - Able to give written informed consent - A clinical diagnosis of Asthma on regular inhaled medication - Measures of poor asthma control: Oral steroid use in the last 12 months and /or ACT score of less than 20 at screening, and/or use of 6 or more short acting beta-agonist inhalers in the last 6 months and/or frequent symptoms and/or (Accident and Emergency) A+E or hospital admission for asthma - Access to the internet at home, use of mobile technology and the ability to operate a web platform in English - No plans to travel abroad for prolonged periods during the trial period - Consent to be contacted by phone, text and email Exclusion Criteria: - Asthma exacerbation in the past 4-6 weeks (Baseline visit to be delayed) . Patients who have a significant medical comorbidity that can present with asthma type symptoms e.g. COPD, Heart Failure, Lung Cancer (these cases require physical examination and a remote assessment would not be appropriate) - Terminal Illness Pregnant - Breast Feeding - Patients who have another medical condition, including but not limited to respiratory immunological or cardiac disease other than asthma deemed by the investigators as significant - Diagnosis of Occupational Asthma - Patients on long term oral steroids or theophylline, as these treatments are not provided by the online doctor service - Previous Intensive Therapy Unit (ITU) admission for asthma - Patients under routine follow up of secondary care for asthmaHousebound - Patients who are unable to read or use an internet-enabled device - Alcohol and drug misuse - Patients deemed unsuitable by their GP - Patients who have another medical treatment(s), including but not limited to beta blockers deemed unsuitable by the investigators. - Already using a self management app. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | my mhealth Limited | Bournemouth | Hampshire |
Lead Sponsor | Collaborator |
---|---|
my mhealth Ltd | CLAHRC Wessex, Expert Health Ltd |
United Kingdom,
Braganza G, Chaudhuri R, McSharry C, Weir CJ, Donnelly I, Jolly L, Lafferty J, Lloyd SM, Spears M, Mair F, Thomson NC. Effects of short-term treatment with atorvastatin in smokers with asthma--a randomized controlled trial. BMC Pulm Med. 2011 Apr 7;11:16. doi: 10.1186/1471-2466-11-16. — View Citation
Braun, V. and Clarke, V. (2006) Using thematic analysis in psychology. Qualitative Research in Psychology, 3 (2). pp. 77-101. ISSN 1478-0887 Available from: http://eprints.uwe.ac.uk/11735
Bunting BA, Cranor CW. The Asheville Project: long-term clinical, humanistic, and economic outcomes of a community-based medication therapy management program for asthma. J Am Pharm Assoc (2003). 2006 Mar-Apr;46(2):133-47. — View Citation
Bussey-Smith KL, Rossen RD. A systematic review of randomized control trials evaluating the effectiveness of interactive computerized asthma patient education programs. Ann Allergy Asthma Immunol. 2007 Jun;98(6):507-16; quiz 516, 566. Review. — View Citation
Car J, Sheikh A. Email consultations in health care: 2--acceptability and safe application. BMJ. 2004 Aug 21;329(7463):439-42. Review. — View Citation
Car J, Sheikh A. Telephone consultations. BMJ. 2003 May 3;326(7396):966-9. Review. — View Citation
Charlton I, White P. Asthma. Chapter 2.4. In: Jones R, Britten N, Culpepper L, Gass DA, Grol R, Mant D, et al. (eds). Oxford Textbook of Primary Medical Care, Vol. 2: clinical management. Oxford: Oxford University Press; 2004. pp. 682-90 20. Asthma UK. An
Coffman JM, Cabana MD, Yelin EH. Do school-based asthma education programs improve self-management and health outcomes? Pediatrics. 2009 Aug;124(2):729-42. doi: 10.1542/peds.2008-2085. Epub 2009 Jul 27. Review. — View Citation
de Jong CC, Ros WJ, Schrijvers G. The effects on health behavior and health outcomes of Internet-based asynchronous communication between health providers and patients with a chronic condition: a systematic review. J Med Internet Res. 2014 Jan 16;16(1):e19. doi: 10.2196/jmir.3000. Review. — View Citation
de Jongh T, Gurol-Urganci I, Vodopivec-Jamsek V, Car J, Atun R. Mobile phone messaging for facilitating self-management of long-term illnesses. Cochrane Database Syst Rev. 2012 Dec 12;12:CD007459. doi: 10.1002/14651858.CD007459.pub2. Review. — View Citation
Deshpande A, Khoja S, Lorca J, McKibbon A, Rizo C, Husereau D, Jadad AR. Asynchronous telehealth: a scoping review of analytic studies. Open Med. 2009 Jun 2;3(2):e69-91. — View Citation
DiBello K, Boyar K, Abrenica S, Worral PS. The effectiveness of text messaging programs on adherence to treatment regimens among adults aged 18 to 45 years diagnosed with asthma: a systematic review. JBI Database of Systematic Reviews and Implementation R
Glaser, BG and Strauss, A. 1967. The discovery of grounded theory: Strategies for qualitative research, Chicago, IL: Aldine.
Guendelman S, Meade K, Benson M, Chen YQ, Samuels S. Improving asthma outcomes and self-management behaviors of inner-city children: a randomized trial of the Health Buddy interactive device and an asthma diary. Arch Pediatr Adolesc Med. 2002 Feb;156(2):1 — View Citation
Harris TJ, Carey IM, Victor CR, Adams R, Cook DG. Optimising recruitment into a study of physical activity in older people: a randomised controlled trial of different approaches. Age Ageing. 2008 Nov;37(6):659-65. doi: 10.1093/ageing/afn159. Epub 2008 Aug 20. — View Citation
Hieftje K, Edelman EJ, Camenga DR, Fiellin LE. Electronic media-based health interventions promoting behavior change in youth: a systematic review. JAMA Pediatr. 2013 Jun;167(6):574-80. doi: 10.1001/jamapediatrics.2013.1095. Review. — View Citation
Leathem CS, Cupples ME, Byrne MC, O'Malley M, Houlihan A, Murphy AW, Smith SM. Identifying strategies to maximise recruitment and retention of practices and patients in a multicentre randomised controlled trial of an intervention to optimise secondary prevention for coronary heart disease in primary care. BMC Med Res Methodol. 2009 Jun 19;9:40. doi: 10.1186/1471-2288-9-40. — View Citation
Levy ML. National Review of Asthma Deaths (NRAD). Br J Gen Pract. 2014 Nov;64(628):564. doi: 10.3399/bjgp14X682237. — View Citation
Marcano Belisario JS, Huckvale K, Greenfield G, Car J, Gunn LH. Smartphone and tablet self management apps for asthma. Cochrane Database Syst Rev. 2013 Nov 27;(11):CD010013. doi: 10.1002/14651858.CD010013.pub2. Review. — View Citation
Matui P, Wyatt JC, Pinnock H, Sheikh A, McLean S. Computer decision support systems for asthma: a systematic review. NPJ Prim Care Respir Med. 2014 May 20;24:14005. doi: 10.1038/npjpcrm.2014.5. Review. — View Citation
McLean S, Sheikh A. Does telehealthcare offer a patient-centred way forward for the community-based management of long-term respiratory disease? Prim Care Respir J. 2009 Sep;18(3):125-6. doi: 10.3132/pcrj.2009.00006. — View Citation
Morrison D, Wyke S, Agur K, Cameron EJ, Docking RI, Mackenzie AM, McConnachie A, Raghuvir V, Thomson NC, Mair FS. Digital asthma self-management interventions: a systematic review. J Med Internet Res. 2014 Feb 18;16(2):e51. doi: 10.2196/jmir.2814. Review. — View Citation
Morrison D, Wyke S, Saunderson K, McConnachie A, Agur K, Chaudhuri R, Thomas M, Thomson NC, Yardley L, Mair FS. Findings from a pilot Randomised trial of an Asthma Internet Self-management Intervention (RAISIN). BMJ Open. 2016 May 12;6(5):e009254. doi: 10.1136/bmjopen-2015-009254. — View Citation
Mukherjee M, Stoddart A, Gupta RP, Nwaru BI, Farr A, Heaven M, Fitzsimmons D, Bandyopadhyay A, Aftab C, Simpson CR, Lyons RA, Fischbacher C, Dibben C, Shields MD, Phillips CJ, Strachan DP, Davies GA, McKinstry B, Sheikh A. The epidemiology, healthcare and — View Citation
Nystuen P, Hagen KB. Telephone reminders are effective in recruiting nonresponding patients to randomized controlled trials. J Clin Epidemiol. 2004 Aug;57(8):773-6. — View Citation
Ofcom, Communications Marketing Report (2015)
Paré G, Moqadem K, Pineau G, St-Hilaire C. Clinical effects of home telemonitoring in the context of diabetes, asthma, heart failure and hypertension: a systematic review. J Med Internet Res. 2010 Jun 16;12(2):e21. doi: 10.2196/jmir.1357. Review. — View Citation
Pope C, Mays N (2006) Qualitative Research in Health Care (3rd Edition) London: BMJ Books.
Schatz M, Kosinski M, Yarlas AS, Hanlon J, Watson ME, Jhingran P. The minimally important difference of the Asthma Control Test. J Allergy Clin Immunol. 2009 Oct;124(4):719-23.e1. doi: 10.1016/j.jaci.2009.06.053. Epub 2009 Sep 19. — View Citation
Treweek S, Pitkethly M, Cook J, Fraser C, Mitchell E, Sullivan F, Jackson C, Taskila TK, Gardner H. Strategies to improve recruitment to randomised trials. Cochrane Database Syst Rev. 2018 Feb 22;2:MR000013. doi: 10.1002/14651858.MR000013.pub6. Review. — View Citation
van der Meer V, Bakker MJ, van den Hout WB, Rabe KF, Sterk PJ, Kievit J, Assendelft WJ, Sont JK; SMASHING (Self-Management in Asthma Supported by Hospitals, ICT, Nurses and General Practitioners) Study Group. Internet-based self-management plus education — View Citation
Wright GR, Howieson S, McSharry C, McMahon AD, Chaudhuri R, Thompson J, Donnelly I, Brooks RG, Lawson A, Jolly L, McAlpine L, King EM, Chapman MD, Wood S, Thomson NC. Effect of improved home ventilation on asthma control and house dust mite allergen levels. Allergy. 2009 Nov;64(11):1671-80. doi: 10.1111/j.1398-9995.2009.02098.x. Epub 2009 Jul 24. — View Citation
* Note: There are 32 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Asthma Control Test (ACT) | The ACT is a validated self administered questionnaire used to evaluate asthma control.ACT assesses the frequency of shortness of breath and general asthma symptoms, use of rescue medications, the effect of asthma on daily functioning | 12 months | |
Secondary | Incidence of treatment emergent Adverse and Serious Adverse Events (Safety and Tolerability | Safety assessed by the incidence of treatment pathway emergent adverse event (AE's) and Serious Adverse Events (SAE's) at study completion. The number of adverse events and serious adverse events will be tabulated also by the number patients reporting an event. | 12 months | |
Secondary | Patient Activation Measurement (PAM) | PAM is a tool used for measuring the level of patient engagement in their healthcare. It was designed to assess an individual's knowledge, skill and confidence for self-management. PAM is a 13-item scale that asks people about their beliefs, knowledge and confidence for engaging in a wide range of health behaviors and then assigns an activation score based on their responses to the 13-item scale. This will be assessed prior to and three months post intervention. | 12 months | |
Secondary | Asthma Exacerbation | Asthma exacerbation data will be collecting from their primary prescriber on their exacerbation history. The numbers of asthma exacerbations requiring oral antibiotics and/or oral steroids by the participants one year prior to starting the study will be recorded at visit one. If the participant has any exacerbations requiring oral antibiotics and/or steroids during the study period this will be recorded during monthly telephone contact with participants and at visit 2 . | 12 months | |
Secondary | Inhaler Technique | This will be assessed using the "7 Steps to successfully inhaler technique developed by the UK Inhaler Group. Each step is evaluated as being Good or Poor and the number of critical errors will be recorded. | 12 months | |
Secondary | Health Care Usage | Change in the median number of hospital and primary care interventions in the 6 months prior to the study and during the study period from baseline to study completion | 12 months | |
Secondary | Medication Adherence | Measure of primary and secondary medication adherence analysing prescription capture data, self-reported data via the MyAsthma app | 12 months | |
Secondary | Lung Function | Mean change in FEV1 from baseline to study completion - FEV1 will be obtained using spirometry. Spirometry will be performed at screening and end of study visit | 12 months | |
Secondary | Fractional Exhaled Nitric Oxide (FENO) | It is a simple breath test that measures the level of Nitric Oxide Concentration that the body naturally produces in the airways. FENo will be measured using a Bedfont device and will be performed at screening visit and end of study visit | 12 months | |
Secondary | Health Economics Analysis | The measurement of health outcome used will be the Quality Adjusted Life Year (QALY) calculated using the EQ5D-5L questionnaire.The EQ5D 5L is a validated questionnaire which comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine.The use of NHS resources from an adjusted baseline period prior to staring the study compared to during the study will be used as a comparator for cost outcomes | 12 months | |
Secondary | Patient Health Questionnaire (PHQ9) | This is a self-administered validated questionnaire which scores each of the nine DSM-IV criteria as 0 (not at all) to 3 (nearly every day) and has been validated for use in primary care. It is not a screening tool for depression but it is used to monitor the severity of depression and response to treatment. Validity has been assessed against an independent structured mental health professional interview. PHQ-9 greater than or equal to 10 had a sensitivity of 88% and specificity of 88% for major depression. The questionnaire can be delivered over the telephone. | 12 month | |
Secondary | General Anxiety Disorder (GAD7) | The GAD-7 is a self-administered validated questionnaire and is used as a screening tool and severity measure for generalised anxiety disorder The GAD-7 score is calculated by assigning scores of 0, 1, 2, and 3, to the response categories of 'not at all', 'several days', 'more than half the days', and 'nearly every day', respectively, and adding together the scores for the seven questions. Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively. When used as a screening tool, further evaluation is recommended when the score is 10 or greater. Using the threshold score of 10, the GAD-7 has a sensitivity of 89% and a specificity of 82% for GAD. It is moderately good at screening three other common anxiety disorders - panic disorder (sensitivity 74%, specificity 81%), social anxiety disorder (sensitivity 72%, specificity 80%) and post-traumatic stress disorder (sensitivity 66%, specificity 81%). | 12 months | |
Secondary | Problematic Experiences of Therapy (PETS) | This is a validated questionnaire which measures difficulties experienced following the advice provided by an intervention.It has 4 domains which cover: 1) Whether symptoms themselves impede ability to follow advice, or are worsened by the advice, 2) Uncertainty about how to follow the advice, 3) Doubts about the efficacy of the app or online advice and 4) Practical obstacles to following the advice such as time or opportunity. | 12 months | |
Secondary | Self Efficacy for Appropriate Medication use Scale (SEAMS) | Was developed by a multidisciplinary team with expertise in medication adherence and health literacy. Its psychometric properties were then evaluated among 436 patients with coronary heart disease among other comorbid conditions. Reliability was evaluated by measuring internal consistency and test-retest reliability. The final 13 item scale showed good internal consistency reliability (Cronbach's alpha= 0.89). The SEAMS is a reliable and valid instrument that may provide a valuable assessment of medication self-efficacy in chronic disease management and appears to also be appropriate for use in patients with low literacy. | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
||
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|